Clinical parameters | Total patients | SOX17 | Total patients | NRF2 | ||
---|---|---|---|---|---|---|
Protein expression | Protein expression | |||||
164 b | N = 52 | N = 112 | 164 b | N = 55 | N = 109 | |
32.1% | 67.9% | 33.5% | 66.5% | |||
High | Low | Low | High | |||
NRF2 | Â | Â | Â | Â | Â | Â |
 Low | 55 | 23 (41.8) | 32 (58.2)0.048 |  |  |  |
 High | 109 | 29 (26.6) | 80 (73.4) |  |  |  |
Age | Â | Â | Â | Â | Â | Â |
 < 55 | 67 | 15 (22.3) | 52 (77.7)0.033 | 67 | 22 (32.8) | 45 (67.2)0.874 |
 ≥ 55 | 97 | 37 (38.1) | 60 (61.9) | 97 | 33 (34.0) | 64 (66.0) |
Sex | Â | Â | Â | Â | Â | Â |
 Male | 157 | 48 (30.6) | 109 (69.4)0.174 | 157 | 52 (33.1) | 105 (66.9)0.593 |
 Female | 7 | 4 (57.1) | 3 (42.9) | 7 | 3 (42.9) | 4 (57.1) |
Smoker | Â | Â | Â | Â | Â | Â |
 No | 22 | 9 (40.9) | 13 (59.1)0.319 | 22 | 11 (50.0) | 11 (50.0)0.079 |
 Yes | 142 | 43 (28.2) | 99 (71.8) | 142 | 44 (31.0) | 98 (69.0) |
Stage | Â | Â | Â | Â | Â | Â |
 I–III | 86 | 32 (37.2) | 54 (62.8)0.112 | 86 | 25 (29.1) | 61 (70.9)0.203 |
 IV | 78 | 20 (25.6) | 58 (74.4) | 78 | 30 (38.5) | 48 (61.5) |
T Stage c |  |  |  |  |  |  |
 I–III | 129 | 41 (31.8) | 88 (68.2)0.949 | 129 | 42 (32.6) | 87 (67.4)0.763 |
 IV | 34 | 11 (32.3) | 23 (67.7) | 34 | 12 (35.3) | 22 (64.7) |
N Stage c |  |  |  |  |  |  |
 0 | 19 | 9 (47.4) | 10 (52.6)0.124 | 19 | 5 (26.3) | 14 (73.7)0.502 |
 1 | 144 | 43 (29.9) | 101 (70.1) | 144 | 49 (34.0) | 95 (66.0) |
M Stage c |  |  |  |  |  |  |
 0 | 85 | 31 (36.5) | 54 (63.5)0.151 | 85 | 25 (29.4) | 60 (70.6)0.266 |
 1 | 77 | 20 (26.0) | 57 (74.0) | 77 | 29 (37.7) | 48 (62.3) |
Response | Â | Â | Â | Â | Â | Â |
 Good | 43 | 21 (48.8) | 22 (51.2)<0.001 | 43 | 30 (69.8) | 13 (30.2)<0.001 |
 Poor | 83 | 12 (14.5) | 71 (85.5) | 83 | 11 (13.3) | 72 (86.7) |